Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

<ul>
<li>Metis TechBio has launched HK IPO consists of 201M shares at HK$10.50 per share. Subscriptions will close on May 8, with the listing slated on May 13.    </li>
<li>The company intends to raise ~$242M to fund R&amp;D of AI infrastructure and AI-driven nanomaterial platforms, and ongoing and planned clinical trials of AI-developed pipeline products.</li>
<li>Metis follows dual-pathway business model that has established a solid commercial foundation. Moreover, possibility of additional product outlicensing deal cannot be ruled out.</li>
</ul>


Metis TechBio has launched HK IPO consists of 201M shares at HK$10.50 per share. Subscriptions will close on May 8, with the listing slated on May 13.    
The company intends to raise ~$242M to fund R&amp;D of AI infrastructure and AI-driven nanomaterial platforms, and ongoing and planned clinical trials of AI-developed pipeline products.
Metis follows dual-pathway business model that has established a solid commercial foundation. Moreover, possibility of additional product outlicensing deal cannot be ruled out.


Metis TechBio IPO: Niche AI Drug Discovery Platform Lays Strong Foundation for Profitable Growth